Drugs / Sym023
Sym023
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04641871 | Oct 2020 → Jun 2024 | metastatic malignant neoplasm | Symphogen A/S | Completed | No outcome recorded |
| Phase 1 | NCT03489343 | May 2018 → Jun 2020 | lymphoma, metastatic malignant neoplasm | Symphogen A/S | Completed | No outcome recorded |
| Phase 1 | NCT03311412 | Nov 2017 → Mar 2022 | lymphoma, metastatic malignant neoplasm | Symphogen A/S | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06162572 | Aug 2024 → Apr 2027 expected | non-small cell lung carcinoma | Servier Bio-Innovation LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06125652 | Nov 2023 → Jan 2026 overdue | acute myeloid leukemia | Xuzhou Medical University | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sym023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04641871 ↗ |
| Known as | anti Tim-3/CD123 CAR-T cell therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06125652 ↗ |
| Known as | Anti-TIM-3 | “Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas” NCT03489343 ↗ |
| Known as | S-95018 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298116 ↗ |
| Known as | S095018 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06162572 ↗ |
| Modality | Monoclonal antibody | “Sym023, a recombinant, fully human, anti-T-cell immunoglobulin and mucin-domain containing-3 (anti-TIM-3) monoclonal antibody (mAb).” NCT03489343 ↗ |
| Route | Intravenous | “each by IV infusion” NCT03311412 ↗ |